Literature DB >> 11685689

Maturation of mass-screened localized adrenal neuroblastoma.

T Iwanaka1, K Yamamoto, Y Ogawa, M Arai, M Ito, H Kishimoto, R Hanada, S Imaizumi.   

Abstract

BACKGROUND/
PURPOSE: In infants, neuroblastoma has been known to spontaneously differentiate into a benign ganglioneuroma. Although several investigators have compared mass-screened with unscreened, disseminated with localized, and adrenal with retroperitoneal neuroblastoma, there are very few cross-comparisons of the above parameters. Herein, the authors report the maturation of mass-screened, localized adrenal neuroblastoma.
METHODS: Fifty-one mass-screened adrenal neuroblastomas were divided into 2 groups. In infants less than 1 year of age (Group A), 45 neuroblastomas were resected, whereas 6 neuroblastomas were resected after observation in 1- to 4-year-old children (group B). Histopathology of the tumors in the 2 groups was compared. Data were analyzed by X(2) test, and P <.05 was considered significant.
RESULTS: According to the International Neuroblastoma Pathological Classification, 41 of 45 tumors of group A were "differentiating neuroblastoma" and 4 of 6 tumors of group B were "maturing ganglioneuroma." Maturation toward ganglioneuroblastoma was observed in 16 neuroblastomas of group A (36%) and 6 neuroblastomas of group B (100%). In group A, 58% had low mitosis karyorrhexis index (MKI); all patients in group B had low MKI.
CONCLUSIONS: If left untreated, maturation of mass-screened, localized adrenal neuroblastomas is a common phenomenon. These children do not need to undergo early operation. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2001        PMID: 11685689     DOI: 10.1053/jpsu.2001.27935

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

1.  Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid.

Authors:  Effie G Halakos; Andrew J Connell; Lisa Glazewski; Shuo Wei; Robert W Mason
Journal:  J Proteomics       Date:  2019-08-28       Impact factor: 4.044

2.  Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis.

Authors:  Indroneil Mukerji; Shakti H Ramkissoon; Kavitha K R Reddy; Pranela Rameshwar
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

3.  Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.

Authors:  Tadaharu Okazaki; Sumio Kohno; Jun-ichi Mimaya; Shiro Hasegawa; Naoto Urushihara; Atsushi Yoshida; Shinya Kawano; Junichi Kusafuka; Yasuo Horikoshi; Yoshifumi Takashima; Katsuhiko Aoki; Minoru Hamazaki
Journal:  Pediatr Surg Int       Date:  2003-12-19       Impact factor: 1.827

4.  Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.

Authors:  Poonam Sonawane; Hwang Eui Cho; Ashujit Tagde; Dattesh Verlekar; Alice L Yu; C Patrick Reynolds; Min H Kang
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  Cutaneous ganglioneuroma within a giant congenital nevus.

Authors:  Marcos Ro Jaeger; Sandra Viero; Ronald M Zuker
Journal:  Can J Plast Surg       Date:  2005

6.  Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease.

Authors:  Morris Kletzel; Pauline M Chou; Marie Olszewski; Alfred W Rademaker; Sana Khan
Journal:  Transl Pediatr       Date:  2015-07

7.  Extirpation of mass-screened adrenal neuroblastomas by retroperitoneoscopy.

Authors:  K Kouch; H Yoshida; T Matsunaga; Y Ohtsuka; T Okada; T Saito; G Matsuura; H Yamada; N Ohnuma
Journal:  Surg Endosc       Date:  2003-06-17       Impact factor: 4.584

8.  Presence of differentiating neuroblasts in bone marrow is a favorable prognostic factor for bone marrow metastatic neuroblastoma at diagnosis.

Authors:  Sang Hyuk Park; Sollip Kim; Chan-Jeoung Park; Seongsoo Jang; Hyun-Sook Chi; Kyung-Nam Koh; Ho Joon Im; Jong Jin Seo
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.